Ontology highlight
ABSTRACT: Objective
To determine whether 18F-THK5351 PET can be used to visualize tau deposits in brain lesions in live patients with corticobasal syndrome (CBS).Methods
We evaluated the in vitro binding of 3H-THK5351 in postmortem brain tissues from a patient with corticobasal degeneration (CBD). In clinical PET studies, 18F-THK5351 retention in 5 patients with CBS was compared to that in 8 age-matched normal controls and 8 patients with Alzheimer disease (AD).Results
3H-THK5351 was able to bind to tau deposits in the postmortem brain with CBD. In clinical PET studies, the 5 patients with CBS showed significantly higher 18F-THK5351 retention in the frontal, parietal, and globus pallidus than the 8 age-matched normal controls and patients with AD. Higher 18F-THK5351 retention was observed contralaterally to the side associated with greater cortical dysfunction and parkinsonism.Conclusions
18F-THK5351 PET demonstrated high tracer signal in sites susceptible to tau deposition in patients with CBS. 18F-THK5351 should be considered as a promising candidate radiotracer for the in vivo imaging of tau deposits in CBS.
SUBMITTER: Kikuchi A
PROVIDER: S-EPMC5135024 | biostudies-literature | 2016 Nov
REPOSITORIES: biostudies-literature
Kikuchi Akio A Okamura Nobuyuki N Hasegawa Takafumi T Harada Ryuichi R Watanuki Shoichi S Funaki Yoshihito Y Hiraoka Kotaro K Baba Toru T Sugeno Naoto N Oshima Ryuji R Yoshida Shun S Kobayashi Junpei J Ezura Michinori M Kobayashi Michiko M Tano Ohito O Mugikura Shunji S Iwata Ren R Ishiki Aiko A Furukawa Katsutoshi K Arai Hiroyuki H Furumoto Shozo S Tashiro Manabu M Yanai Kazuhiko K Kudo Yukitsuka Y Takeda Atsushi A Aoki Masashi M
Neurology 20161028 22
<h4>Objective</h4>To determine whether <sup>18</sup>F-THK5351 PET can be used to visualize tau deposits in brain lesions in live patients with corticobasal syndrome (CBS).<h4>Methods</h4>We evaluated the in vitro binding of <sup>3</sup>H-THK5351 in postmortem brain tissues from a patient with corticobasal degeneration (CBD). In clinical PET studies, <sup>18</sup>F-THK5351 retention in 5 patients with CBS was compared to that in 8 age-matched normal controls and 8 patients with Alzheimer disease ...[more]